Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study

Background and objectives: It is necessary to expand the knowledge in the use of apremilast in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the characteristics of patients with psoriasis treated with apremilast, to evaluate their perspectives and those of dermatologists, as...

Descripción completa

Detalles Bibliográficos
Autores: Herranz, Pedro, Trasobares, L., Mateu, A., Ruiz-Villaverde, R., Baniandres, O., Mataix Diaz, J., Jimenez-Gomez, N., Serra, M., Ruiz Genao, D. P., Rivera, N., Tercedor-Sanchez, J., Garcia, C., Cordey, M., Herrera-Acosta, E.
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:español
OAI Identifier:oai:docusalut.com:20.500.13003/19486
Acceso en línea:https://hdl.handle.net/20.500.13003/19486
Access Level:acceso abierto
Palabra clave:Apremilast
Psoriasis
Clinical practice
Therapeutic benefits
id ES_daae56d79acee00d8eee6691cdd6a1ed
oai_identifier_str oai:docusalut.com:20.500.13003/19486
network_acronym_str ES
network_name_str España
repository_id_str
spelling Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE StudyHerranz, PedroTrasobares, L.Mateu, A.Ruiz-Villaverde, R.Baniandres, O.Mataix Diaz, J.Jimenez-Gomez, N.Serra, M.Ruiz Genao, D. P.Rivera, N.Tercedor-Sanchez, J.Garcia, C.Cordey, M.Herrera-Acosta, E.ApremilastPsoriasisClinical practiceTherapeutic benefitsBackground and objectives: It is necessary to expand the knowledge in the use of apremilast in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the characteristics of patients with psoriasis treated with apremilast, to evaluate their perspectives and those of dermatologists, as well as the outcomes obtained in clinical practice in Spain. Methods: Observational, retrospective, cross-sectional, multicenter study of patients with chronic plaque psoriasis who could be contacted 6 (+/- 1) months after apremilast initiation. The data were obtained from medical records and questionnaires from patients and physicians. Results: A total of 80 patients were evaluated; at apremilast onset, they showed mean (standard deviation, SD) Psoriasis Area and Severity Index (PASI) = 8.3 (5.3), mean (SD) Dermatology Life Quality Index (DLQI) = 8.9 (6.6). At six months, 58.8% (n=47) of patients continued apremilast treatment (discontinuations due to lack of efficacy [16.3%], safety/tolerability [20.0%]). In patients continuing treatment, PASI75 was achieved by 36.7% of patients; mean (95% CI) DLQI score was 2.2 (0.7-3.6) and mean (SD) Patient Benefit Index score was 2.8 (0.8). Compliance with physicians' expectations was correlated with benefits reported by patients (r=0.636). Adverse events were reported by 56.3% of patients (the most common were diarrhoea and nausea). Conclusions: Patients receiving apremilast for 6 months in Spanish clinical practice, reported substantial improvements in their quality of life (mean DLQI reduced by more than 6 points) and disease severity (PASI75 achieved by over one-third of patients), despite less skin involvement than patients who enrolled in clinical trials. (C) 2021 AEDV. Published by Elsevier Espana, S.L.U.Elsevier Espana20212021-10-0120212021-10-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/19486reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsEspañolspaopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/194862026-06-22T12:44:07Z
dc.title.none.fl_str_mv Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
title Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
spellingShingle Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
Herranz, Pedro
Apremilast
Psoriasis
Clinical practice
Therapeutic benefits
title_short Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
title_full Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
title_fullStr Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
title_full_unstemmed Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
title_sort Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
dc.creator.none.fl_str_mv Herranz, Pedro
Trasobares, L.
Mateu, A.
Ruiz-Villaverde, R.
Baniandres, O.
Mataix Diaz, J.
Jimenez-Gomez, N.
Serra, M.
Ruiz Genao, D. P.
Rivera, N.
Tercedor-Sanchez, J.
Garcia, C.
Cordey, M.
Herrera-Acosta, E.
author Herranz, Pedro
author_facet Herranz, Pedro
Trasobares, L.
Mateu, A.
Ruiz-Villaverde, R.
Baniandres, O.
Mataix Diaz, J.
Jimenez-Gomez, N.
Serra, M.
Ruiz Genao, D. P.
Rivera, N.
Tercedor-Sanchez, J.
Garcia, C.
Cordey, M.
Herrera-Acosta, E.
author_role author
author2 Trasobares, L.
Mateu, A.
Ruiz-Villaverde, R.
Baniandres, O.
Mataix Diaz, J.
Jimenez-Gomez, N.
Serra, M.
Ruiz Genao, D. P.
Rivera, N.
Tercedor-Sanchez, J.
Garcia, C.
Cordey, M.
Herrera-Acosta, E.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Apremilast
Psoriasis
Clinical practice
Therapeutic benefits
topic Apremilast
Psoriasis
Clinical practice
Therapeutic benefits
description Background and objectives: It is necessary to expand the knowledge in the use of apremilast in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the characteristics of patients with psoriasis treated with apremilast, to evaluate their perspectives and those of dermatologists, as well as the outcomes obtained in clinical practice in Spain. Methods: Observational, retrospective, cross-sectional, multicenter study of patients with chronic plaque psoriasis who could be contacted 6 (+/- 1) months after apremilast initiation. The data were obtained from medical records and questionnaires from patients and physicians. Results: A total of 80 patients were evaluated; at apremilast onset, they showed mean (standard deviation, SD) Psoriasis Area and Severity Index (PASI) = 8.3 (5.3), mean (SD) Dermatology Life Quality Index (DLQI) = 8.9 (6.6). At six months, 58.8% (n=47) of patients continued apremilast treatment (discontinuations due to lack of efficacy [16.3%], safety/tolerability [20.0%]). In patients continuing treatment, PASI75 was achieved by 36.7% of patients; mean (95% CI) DLQI score was 2.2 (0.7-3.6) and mean (SD) Patient Benefit Index score was 2.8 (0.8). Compliance with physicians' expectations was correlated with benefits reported by patients (r=0.636). Adverse events were reported by 56.3% of patients (the most common were diarrhoea and nausea). Conclusions: Patients receiving apremilast for 6 months in Spanish clinical practice, reported substantial improvements in their quality of life (mean DLQI reduced by more than 6 points) and disease severity (PASI75 achieved by over one-third of patients), despite less skin involvement than patients who enrolled in clinical trials. (C) 2021 AEDV. Published by Elsevier Espana, S.L.U.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-10-01
2021
2021-10-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/19486
url https://hdl.handle.net/20.500.13003/19486
dc.language.none.fl_str_mv Español
spa
language_invalid_str_mv Español
language spa
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier Espana
publisher.none.fl_str_mv Elsevier Espana
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421602352922624
score 15.812429

Similares en LA Referencia